RU95120569A - NEW DERIVATIVES 5-pyrrolyl-2-pyridylmethylsulfonyl-benzimidazole - Google Patents
NEW DERIVATIVES 5-pyrrolyl-2-pyridylmethylsulfonyl-benzimidazoleInfo
- Publication number
- RU95120569A RU95120569A RU95120569/04A RU95120569A RU95120569A RU 95120569 A RU95120569 A RU 95120569A RU 95120569/04 A RU95120569/04 A RU 95120569/04A RU 95120569 A RU95120569 A RU 95120569A RU 95120569 A RU95120569 A RU 95120569A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- alkyl
- hydrogen
- independently
- formula
- Prior art date
Links
- OTKUEHPBPOIITA-UHFFFAOYSA-N N1C(=CC=C1)C=1C=CC(=NC=1)CS(=O)(=O)C=1NC2=C(N=1)C=CC=C2 Chemical compound N1C(=CC=C1)C=1C=CC(=NC=1)CS(=O)(=O)C=1NC2=C(N=1)C=CC=C2 OTKUEHPBPOIITA-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000006550 alkoxycarbonyl aryl group Chemical group 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- -1 methoxy, ethoxy, 2,2,2-trifluoroethoxy Chemical group 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 230000000767 anti-ulcer Effects 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001590 oxidative Effects 0.000 claims 1
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (10)
и его соль, в которой:
Х представляет S, SO или SO2,
R1 и R2 независимо друг от друга представляют водород или алкил;
R3 представляет водород, С1-С8-алкил, -SR6, -N(R7)2, 1- пиперидинил, 4-морфолинил, 4-метилпиперазин-1-ил, 1- пирролидинил, -ОR6 или -O(СН2)m-Z, где R6 представляет С1-С4-алкил, С2-С4-алкенил, С3-С10- циклоалкил, С2-С5-фторалкил, или фенил, или бензил, каждый из которых независимо замещен одним или несколькими галогенами или С1-С4-алкилом или алкокси, необязательно замещенным галогеном;
R7 представляет водород или С1-С5-алкил;
Z представляет группу -O(СН2)р-ОR8, -O(СН2)q-R9 или O(СН2)rО(СН2)s-ОR10, где р и q независимо друг от друга означают целое число от 1 до 3; r и s независимо друг от друга означают целое число от 1 до 5,
R8 представляет водород, низший алкил, арил или аралкил;
R9 представляет водород, алкоксикарбонил, арил или гетероарил;
R10 представляет водород или низший алкил; m представляет целое число от 2 до 10; R4 и R5 независимо друг от друга представляют водород или С1-С5-алкил, или когда R4 и R5 вместе с углеродными атомами, смежными с пиридиновым кольцом, образуют кольцо;
R4 и R3 или R3 и R5 представляют -СН=СН-СН=СН-, -O(СН2)n-, - O(СН2)nО-, -СН2(СН2)n- или -ОСН=СН-, где n означает целое число от 1 до 4.1. The compound having the following General formula (I):
and its salt, in which:
X represents S, SO or SO 2 ,
R 1 and R 2 independently of one another represent hydrogen or alkyl;
R 3 is hydrogen, C 1 -C 8 -alkyl, -SR 6 , -N (R 7 ) 2 , 1-piperidinyl, 4-morpholinyl, 4-methylpiperazin-1-yl, 1-pyrrolidinyl, -OR 6 or - O (CH 2 ) m —Z, where R 6 is C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 3 -C 10 - cycloalkyl, C 2 -C 5 -fluoroalkyl, or phenyl, or benzyl , each of which is independently substituted with one or more halogen or C 1 -C 4 -alkyl or alkoxy, optionally substituted with halogen;
R 7 represents hydrogen or C 1 -C 5 -alkyl;
Z represents a group —O (CH 2 ) p —OR 8 , —O (CH 2 ) q —R 9 or O (CH 2 ) r O (CH 2 ) s —OR 10 , where p and q independently mean an integer from 1 to 3; r and s independently of one another denote an integer from 1 to 5,
R 8 represents hydrogen, lower alkyl, aryl or aralkyl;
R 9 is hydrogen, alkoxycarbonyl, aryl or heteroaryl;
R 10 is hydrogen or lower alkyl; m is an integer from 2 to 10; R 4 and R 5 independently of one another represent hydrogen or C 1 -C 5 -alkyl, or when R 4 and R 5 together with carbon atoms adjacent to the pyridine ring form a ring;
R 4 and R 3 or R 3 and R 5 represent-CH = CH-CH = CH-, -O (CH 2 ) n -, - O (CH 2 ) n O-, -CH 2 (CH 2 ) n - or -OCH = CH-, where n is an integer from 1 to 4.
R1 и R2 независимо друг от друга представляют водород или алкил;
R3 представляет водород, С1-С8-алкил, -SR6, -N(R7)2, 1- пиперидинил, 4-морфолинил, 4-метилпиперазин-1-ил, 1- пирролидинил, -OR6, или -O(СН2)m-Z, где R6 представляет С1-С4-алкил, С2-С4-алкенил, С3-С10-циклоалкил, необязательно замещенный С1-С4-алкилом, C2-C5- фторалкил, имеющий от 3 до 8 атомов фтора, или фенил, или бензил, каждый из которых независимо замещен одним или несколькими галогенами или С1-C4-алкилом или алкокси, необязательно замещенным галогеном;
R7 представляет водород или С1-C4-алкил,
Z представляет группу -O(СН2)р-ОR8, -O(CH2)q-R9 или O(СН2)rО(СН2)s-ОR10, где р и q независимо друг от друга означают целое число от 1 до 3, r и s независимо друг от друга означают целое число от 1 до 5,
R8 представляет водород, низший алкил, арил или аралкил;
R9 представляет водород, алкоксикарбонил, арил или гетероарил, и
R10 представляет водород или низший алкил;
m представляет целое число от 2 до 10
R4 и R5 независимо друг от друга представляют водород или С1-С5-алкил,
или когда R4 и R5 вместе с углеродными атомами, смежными с пиридиновым кольцом, образуют кольцо, R4 и R3 или R3 и R5 представляют -СН=СН-СН=СН-, -O(СН2)n-, -СН2(СН2)n- или -ОСН=СН-, где n означает целое число от 2 до 4, и атом кислорода должен присутствовать в R3-положении.2. The compound of formula (I) according to claim 1, where X is S, SO or SO 2 ;
R 1 and R 2 independently of one another represent hydrogen or alkyl;
R 3 is hydrogen, C 1 -C 8 -alkyl, -SR 6 , -N (R 7 ) 2 , 1-piperidinyl, 4-morpholinyl, 4-methylpiperazin-1-yl, 1-pyrrolidinyl, -OR 6 , or —O (CH 2 ) m —Z, where R 6 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 3 -C 10 cycloalkyl, optionally substituted with C 1 -C 4 alkyl, C 2 -C 5 - fluoroalkyl having from 3 to 8 fluorine atoms, or phenyl, or benzyl, each of which is independently substituted with one or more halogens or C 1 -C 4 alkyl or alkoxy, optionally substituted with halogen;
R 7 represents hydrogen or C 1 -C 4 -alkyl,
Z represents a group —O (CH 2 ) p —OR 8 , —O (CH 2 ) q —R 9 or O (CH 2 ) r O (CH 2 ) s —OR 10 , where p and q independently mean an integer from 1 to 3, r and s independently from each other mean an integer from 1 to 5,
R 8 represents hydrogen, lower alkyl, aryl or aralkyl;
R 9 is hydrogen, alkoxycarbonyl, aryl or heteroaryl, and
R 10 is hydrogen or lower alkyl;
m represents an integer from 2 to 10
R 4 and R 5 independently of one another represent hydrogen or C 1 -C 5 -alkyl,
or when R 4 and R 5, together with carbon atoms adjacent to the pyridine ring, form a ring, R 4 and R 3 or R 3 and R 5 represent -CH = CH-CH = CH-, -O (CH 2 ) n - , -CH 2 (CH 2 ) n - or -OCH = CH-, where n means an integer from 2 to 4, and the oxygen atom must be present in the R 3 position.
R1 и R2 независимо друг от друга представляют водород или метил;
R3 представляет водород, метил, метокси, этокси, 2,2,2- трифторэтокси или 3,3,3,2,2-пентафторпропокси;
R4 представляет водород или метил;
R5 представляет водород, метил или этил.3. The compound of formula (I) according to claim 2, wherein X is S, SO, or SO 2 ,
R 1 and R 2 independently of one another represent hydrogen or methyl;
R 3 is hydrogen, methyl, methoxy, ethoxy, 2,2,2-trifluoroethoxy or 3,3,3,2,2-pentafluoropropoxy;
R 4 represents hydrogen or methyl;
R 5 represents hydrogen, methyl or ethyl.
R1 и R2 независимо друг от друга представляют водород,
R3 представляет метокси или этокси
и R4 и R5 независимо друг от друга представляют водород, метил или этил.4. The compound of formula (I) according to claim 1, wherein X is SO;
R 1 and R 2 independently of one another represent hydrogen,
R 3 is methoxy or ethoxy
and R 4 and R 5 independently of one another represent hydrogen, methyl or ethyl.
где R1 и R2 определены так, как они описаны в п.1,
подвергают реакции с соединением, имеющим следующую общую формулу (III):
где R3, R4 и R5 определены так, как они описаны в п.1, и Y представляет галоген, этерифицированную гидрокси или ацилоксигруппу,
в органическом растворителе в присутствии основания, или
(в) соединение, имеющее следующую общую формулу (IV):
где R1 и R2 определены так, как они описаны в п.1, t представляет 1 или 2 и М представляет щелочной металл,
подвергают реакции с соединением, имеющим следующую общую формулу (V):
где R3, R4 и R5 определены так, как они описаны в п.1,
или (с) соединение, имеющее следующую общую формулу (VI):
где R1 и R2 определены так, как они описаны в п.1,
подвергают реакции с соединением, имеющим следующую общую формулу (VII):
где R3, R4 и R5 определены так, как они описаны в п.1,
или (d) соединение, имеющее следующую общую формулу (VIII):
где R1 и R2 определены так, как они описаны в п.1,
подвергают реакции с соединением, имеющим следующую общую формулу (IX):
где R3, R4 и R5 определены так, как они описаны в п.1,
в полярном растворителе в присутствии сильной кислоты.5. The method of obtaining the compounds of formula (I) according to claim 1, characterized in that (a) a compound having the following formula (II):
where R 1 and R 2 defined as they are described in claim 1,
subjected to reaction with a compound having the following general formula (III):
where R 3 , R 4 and R 5 are defined as described in claim 1, and Y is a halogen, esterified hydroxy or acyloxy group,
in an organic solvent in the presence of a base, or
(c) a compound having the following general formula (IV):
where R 1 and R 2 are defined as described in claim 1, t is 1 or 2 and M is an alkali metal,
subjected to reaction with a compound having the following general formula (V):
where R 3 , R 4 and R 5 are defined as described in claim 1,
or (c) a compound having the following general formula (VI):
where R 1 and R 2 defined as they are described in claim 1,
subjected to reaction with a compound having the following general formula (VII):
where R 3 , R 4 and R 5 are defined as described in claim 1,
or (d) a compound having the following general formula (VIII):
where R 1 and R 2 defined as they are described in claim 1,
subjected to reaction with the compound having the following general formula (IX):
where R 3 , R 4 and R 5 are defined as described in claim 1,
in a polar solvent in the presence of a strong acid.
где X, R1, R2, R3, R4 и R5 определены так, как они описаны в п. 1,
для соединения формулы (I) вместе с его фармацевтически приемлемым носителем, адьювантом или эксипиентом.10. An anti-ulcer composition comprising as an active ingredient an effective amount of a compound having the following general formula (I):
where X, R 1 , R 2 , R 3 , R 4 and R 5 are defined as they are described in paragraph 1,
for the compound of formula (I) together with its pharmaceutically acceptable carrier, adjuvant or excipient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1994/3833 | 1994-02-28 | ||
KR1019940003833A KR0179401B1 (en) | 1994-02-28 | 1994-02-28 | Novel 5-pyrrolyl-2-pyridylmethylsulfanilbenzimidazole derivatives |
PCT/KR1994/000098 WO1995023140A1 (en) | 1994-02-28 | 1994-07-22 | Novel 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95120569A true RU95120569A (en) | 1997-09-20 |
RU2100358C1 RU2100358C1 (en) | 1997-12-27 |
Family
ID=19378085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU9595120569A RU2100358C1 (en) | 1994-02-28 | 1994-07-22 | Derivatives of 5-pyrrolyl-2-pyridylmethylsulfonylbenzimidazole or their salts and a method of their synthesis |
Country Status (17)
Country | Link |
---|---|
US (1) | US5703097A (en) |
EP (1) | EP0696281B1 (en) |
JP (1) | JP2690621B2 (en) |
KR (1) | KR0179401B1 (en) |
CN (1) | CN1048245C (en) |
AT (1) | ATE179976T1 (en) |
AU (1) | AU675564B2 (en) |
BR (1) | BR9406362A (en) |
CA (1) | CA2161542C (en) |
DE (1) | DE69418461T2 (en) |
DK (1) | DK0696281T3 (en) |
ES (1) | ES2132415T3 (en) |
HU (1) | HU220047B (en) |
RU (1) | RU2100358C1 (en) |
TW (1) | TW263499B (en) |
WO (1) | WO1995023140A1 (en) |
ZA (1) | ZA945621B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
AU6551198A (en) * | 1997-05-30 | 1998-12-30 | Dr. Reddy's Research Foundation | Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them |
KR100299562B1 (en) * | 1998-12-29 | 2001-11-22 | 우재영 | 5-Pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivative-containing microgranules for maximum stability |
US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
KR100359256B1 (en) * | 1999-10-06 | 2002-11-04 | 한미약품공업 주식회사 | Improved method of preparing lansoprazole |
SG105539A1 (en) * | 2002-03-01 | 2004-08-27 | Il Yang Pharm Co Ltd | Stabilized enteric-coated microgranules comprising 2-[(4-methoxy-3-methyl)-2-pyridinyl] methylsulfinyl-5-(1h-pyrrol-1-yl)-1h-benzimidazole and oral formulations comprising the microgranules |
CA2493618A1 (en) * | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
EP1861391B1 (en) * | 2005-03-25 | 2011-10-12 | Livzon Pharmaceutical Group Inc. | Methods for preparing substituted sulfoxide compounds |
CN101098867B (en) * | 2005-03-25 | 2010-08-11 | 丽珠医药集团股份有限公司 | Substituted sulfoxide compound and its preparing method and application |
KR101148399B1 (en) * | 2005-06-22 | 2012-05-23 | 일양약품주식회사 | Pharmaceutical Composition for Treating Gastric Disease Containing Antiulcerent and Mucosal Protective Agents |
EP1971327A4 (en) * | 2005-12-16 | 2009-09-23 | Takeda Pharmaceuticals North A | Pharmaceutical compositions of ilaprazole |
CA2657346A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | Formulations for benzimidazolyl pyridyl ethers |
US20100317689A1 (en) * | 2006-09-19 | 2010-12-16 | Garst Michael E | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
WO2008057802A2 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
WO2008083319A1 (en) * | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
KR20110091594A (en) * | 2006-12-29 | 2011-08-11 | 일양약품주식회사 | Solid state forms of racemic ilaprazole |
WO2008130863A2 (en) * | 2007-04-11 | 2008-10-30 | Auspex Pharmaceuticals, Inc. | Substituted benzimidazoles |
KR101044880B1 (en) | 2008-06-12 | 2011-06-28 | 일양약품주식회사 | Process for Preparing Intermediate Compound for Synthesizing an Antiulcerant |
CZ302548B6 (en) * | 2008-10-22 | 2011-07-07 | Zentiva, A.S. | Process for preparing 5-amino-2-[(4-methoxy-3-methyl-2-pyridyl)-methylthio]-1H-benzimidazole and 5-(1H-pyrrol-1-yl)-2-[(4-methoxy-3-methyl-2-pyridyl)-methylthio]-1H-benzimidazole |
CN102140092B (en) * | 2010-02-03 | 2013-05-29 | 丽珠医药集团股份有限公司 | Hydrate of ilaprazole salt, preparation method thereof and application thereof |
CN104203938A (en) | 2012-01-21 | 2014-12-10 | 朱比兰特生命科学有限公司 | Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers |
CN103073536B (en) * | 2013-01-17 | 2015-06-24 | 丽珠医药集团股份有限公司 | Preparation method of ilaprazole |
CN105218522B (en) * | 2014-06-25 | 2019-04-02 | 江苏奥赛康药业股份有限公司 | A kind of dextrorotation Iprazole compound and its pharmaceutical composition |
CN105461692A (en) * | 2014-09-04 | 2016-04-06 | 江苏奥赛康药业股份有限公司 | Ilaprazole sodium compound and pharmaceutical composition thereof |
CN116462666A (en) | 2017-01-10 | 2023-07-21 | 瑞士苏黎世联邦理工学院 | Cytoprotective compounds and uses thereof |
KR102027388B1 (en) | 2017-11-15 | 2019-10-01 | 주식회사 다산제약 | Process for preparing high purity ilaprazole crystalline form B |
CN108685918B (en) * | 2018-06-22 | 2021-02-09 | 丽珠医药集团股份有限公司 | Pharmaceutical composition containing ilaprazole or salt thereof and preparation method thereof |
CN109053685B (en) * | 2018-06-22 | 2020-09-22 | 丽珠医药集团股份有限公司 | Pharmaceutical composition containing ilaprazole sodium and preparation method thereof |
KR102250509B1 (en) | 2020-12-09 | 2021-05-11 | 유니셀랩 주식회사 | Novel co-crystal of ilaprazole/xylitol |
CN114163419A (en) * | 2021-12-24 | 2022-03-11 | 辰欣药业股份有限公司 | Preparation method of lansoprazole |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1234058A (en) * | 1968-10-21 | 1971-06-03 | ||
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
US4225431A (en) * | 1978-12-28 | 1980-09-30 | Pepsico, Inc. | Process and apparatus for the treatment of aqueous waste materials |
SE8300736D0 (en) * | 1983-02-11 | 1983-02-11 | Haessle Ab | NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6185383A (en) * | 1984-10-02 | 1986-04-30 | Banyu Pharmaceut Co Ltd | Benzimidazole derivative, its preparation, and pharmaceutical containing same |
JPS62108879A (en) * | 1985-11-05 | 1987-05-20 | Grelan Pharmaceut Co Ltd | Substituted benzimidazole |
FI90544C (en) * | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Process for Preparation as Drug Useful 2-Pyridin-2-yl-methylthio- and sulfinyl-1H-benzimidazole derivatives |
KR0142815B1 (en) * | 1994-12-02 | 1998-07-15 | 정도언 | Novel 5-pyrrolyl-o-halogeno-2-pyridyl methylsulfinylbenzimidazole derivatlves |
-
1994
- 1994-02-28 KR KR1019940003833A patent/KR0179401B1/en not_active IP Right Cessation
- 1994-07-22 EP EP94921865A patent/EP0696281B1/en not_active Expired - Lifetime
- 1994-07-22 CA CA002161542A patent/CA2161542C/en not_active Expired - Lifetime
- 1994-07-22 AU AU72399/94A patent/AU675564B2/en not_active Expired
- 1994-07-22 AT AT94921865T patent/ATE179976T1/en active
- 1994-07-22 WO PCT/KR1994/000098 patent/WO1995023140A1/en active IP Right Grant
- 1994-07-22 BR BR9406362A patent/BR9406362A/en not_active Application Discontinuation
- 1994-07-22 CN CN94191913A patent/CN1048245C/en not_active Expired - Lifetime
- 1994-07-22 JP JP7522268A patent/JP2690621B2/en not_active Expired - Lifetime
- 1994-07-22 DK DK94921865T patent/DK0696281T3/en active
- 1994-07-22 HU HU9503401A patent/HU220047B/en unknown
- 1994-07-22 RU RU9595120569A patent/RU2100358C1/en active
- 1994-07-22 ES ES94921865T patent/ES2132415T3/en not_active Expired - Lifetime
- 1994-07-22 DE DE69418461T patent/DE69418461T2/en not_active Expired - Lifetime
- 1994-07-22 US US08/537,846 patent/US5703097A/en not_active Expired - Lifetime
- 1994-07-27 TW TW083106846A patent/TW263499B/zh not_active IP Right Cessation
- 1994-07-29 ZA ZA945621A patent/ZA945621B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95120569A (en) | NEW DERIVATIVES 5-pyrrolyl-2-pyridylmethylsulfonyl-benzimidazole | |
KR950025038A (en) | Novel 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivatives | |
RU2309951C2 (en) | Nicotinamide derivatives, methods for their preparing, pharmaceutical composition based on thereof and using | |
RU98119523A (en) | COMPOUNDS OF PIPERAZIN AND PIPERIDINE | |
RU96119964A (en) | NAFTYLAMIDES AS MEANS OF IMPACT ON THE CENTRAL NERVOUS SYSTEM | |
RU2006101987A (en) | TRICYCLIC DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHODS FOR PRODUCING THERE AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
SE8000920L (en) | 4- (naphthylmethyl) PIPERIDINE DERIVATIVES | |
RU2001117070A (en) | Derivatives of dibenzene [a, g] quinolysinium and their salts | |
AU601687B2 (en) | New derivatives of carboxamide indole, their salts, process and intermediates for preparation, use as medicaments and compositions containing them | |
RU2001109228A (en) | Unsaturated derivatives of hydroxy acid as inhibitors of NAD + -ADP-ribosyltransferase | |
RU2003114754A (en) | METHOD FOR PRODUCING BISBENZAZOZYL COMPOUNDS | |
DK5086A (en) | AMINOAL COOL SUBSTITUTED URINE DERIVATIVES AND ENANTIOMERS | |
EP0397613A3 (en) | Pharmacologically active aminoimidazopyridines | |
FI974435A (en) | Process for the conversion of 2,4-dichloropyridines to 2-aryloxy-4-chloropyridines | |
IL83367A0 (en) | 3-aryl-3-cycloalkyl-piperidine-2,6-dione derivatives,their preparation and pharmaceutical compositions containing them | |
RU99113432A (en) | NEW DERIVATIVES OF PHENANTRIDINIA | |
IE43248L (en) | Araliphatic dihalogen compounds. | |
UA72949C2 (en) | A PROCESS FOR THE PREPARATION OF {2-[4-(a-PHENYL-P-CHLOROBENZENE-1-YL]-ETHOXY}ACETIC ACID AND INTERMEDIARY COMPOUNDS | |
SE8005493L (en) | 4- (HAFTALENYLOXI) PIPERIDINE DERIVATIVES | |
KR920009826A (en) | Piperazino alkylbenzoxazines and piperazinoalkyl benzothiazine compounds substituted with heterocycles, methods for their preparation and agents containing the compounds | |
RU97118593A (en) | DERIVATIVES OF 1- [ω- (3,4-DIHYDRO-2-NAFTALINIL) ALKYL] CYCLIC AMINE, METHOD OF THEIR RECEIVING AND CONTAINING THEIR PHARMACEUTICAL COMPOSITION | |
EP0216542B1 (en) | Dihydropyridine derivatives | |
EA200100344A3 (en) | New cyclobutaindolecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them | |
JPS5251382A (en) | Preparation of novel morpholine derivatives and acid addiio salts ther eof | |
DK601983A (en) | AMINOETHOXYBENZYL ALCOHOL DERIVATIVES |